Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Appili Therapeutics Inc
(TSX:
APLI
)
0.0400
UNCHANGED
Streaming Delayed Price
Updated: 3:53 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Appili Therapeutics Inc
< Previous
1
2
Next >
TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics (TSX: APLI) (OTC: APLIF) Enter Third Amending Agreement
August 21, 2024
Via
Investor Brand Network
Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics
August 21, 2024
From
Aditxt, Inc.
Via
Business Wire
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics Sign Second Amendent to Acquisition Agreement
July 25, 2024
Via
Investor Brand Network
Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition
July 25, 2024
From
Aditxt, Inc.
Via
Business Wire
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
April 02, 2024
From
Aditxt, Inc.
Via
Business Wire
Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan
December 15, 2023
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024
November 13, 2023
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy
October 25, 2023
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update
September 27, 2023
From
Appili Therapeutics
Via
Business Wire
Appili Therapeutics Presents at the 10th International Tularemia Conference
September 27, 2023
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension
September 25, 2023
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024
August 11, 2023
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics – Press Release Correction
June 23, 2023
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results
June 23, 2023
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole
May 24, 2023
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer
April 03, 2023
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023
February 14, 2023
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program
January 17, 2023
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole
January 13, 2023
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy
November 14, 2022
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023
November 10, 2022
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
September 22, 2022
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2023
August 12, 2022
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia
August 02, 2022
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Reports Fiscal Year 2022 Financial and Operational Results
June 29, 2022
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
April 27, 2022
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis
April 13, 2022
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Announces Over US$10 Million in New Funding from US Department of Defense for Biodefense Vaccine Candidate ATI-1701
February 28, 2022
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2022
February 14, 2022
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals
February 08, 2022
From
Appili Therapeutics Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.